• 沒有找到結果。

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events.

N/A
N/A
Protected

Academic year: 2021

Share "Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events."

Copied!
1
0
0

加載中.... (立即查看全文)

全文

(1)

Telmisartan, Ramipril, or Both in Patients at High

Risk for Vascular Events

程俊傑

JJ CHENG

摘要

Abstract

Background In patients who have vascular disease or high-risk diabetes without heart failure,

angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes.

Methods After a 3-week, single-blind run-in period, patients underwent double-blind randomization, with 8576 assigned to receive 10 mg of ramipril per day, 8542 assigned to receive 80 mg of telmisartan per day, and 8502 assigned to receive both drugs (combination therapy). The primary composite outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure.

Results Mean blood pressure was lower in both the telmisartan group (a 0.9/0.6 mm Hg greater reduction) and the combination-therapy group (a 2.4/1.4 mm Hg greater reduction) than in the ramipril group. At a median follow-up of 56 months, the primary outcome had occurred in 1412 patients in the ramipril group (16.5%), as compared with 1423 patients in the telmisartan group (16.7%; relative risk, 1.01; 95% confidence interval [CI], 0.94 to 1.09). As compared with the ramipril group, the telmisartan group had lower rates of cough (1.1% vs. 4.2%, P<0.001) and angioedema (0.1% vs. 0.3%, P=0.01) and a higher rate of hypotensive symptoms (2.6% vs. 1.7%, P<0.001); the rate of syncope was the same in the two groups (0.2%). In the combination-therapy group, the primary outcome occurred in 1386 patients (16.3%; relative risk, 0.99; 95% CI, 0.92 to 1.07); as compared with the ramipril group, there was an increased risk of hypotensive symptoms (4.8% vs. 1.7%, P<0.001), syncope (0.3% vs. 0.2%, P=0.03), and renal dysfunction (13.5% vs. 10.2%, P<0.001).

參考文獻

相關文件

patients with stage I/II disease but not in those with stage III disease.43 A high serum level of VEGF is associated with poor survival among patients with small cell lung

Clinical findings and risk factors to oral squamous cell carcinoma in young patients: A 12-year retrospective analysis.. Hellen-Bandeira-de-Pontes Santos 1 , Thayana-Karla-Guerra

According to his protocol, patients are categorised as Stage I if they exhibit exposed bone in a field of radiation that has failed to heal for at least 6 months and do not have

Radiomorphometric indices can be used to deter- mine the existence of a porous structure in the man- dible on panoramic images of patients who have scleroderma and may have a high

In this respect, the aim of the present study was to as- sess volumetric as well as morphological surface changes of the orbital cavity in patients treated with both tooth- borne

A discussion of the Dapagli flozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, the Effect of Sotagli flozin on Car- diovascular Events in Patients

„  Exploit antenna diversity to increase the SNR of a single stream. „  Receive diversity and

„  Exploit antenna diversity to increase the SNR of a single stream. „  Receive diversity and